Menu
Back to User profile » Dr Sai-Hong Ou
Papers published by Dr Sai-Hong Ou:
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.
Ou SI, Le X, Nagasaka M, Reungwetwattana T, Ahn MJ, Lim DW, Santos ES, Shum E, Lau SC, Lee JB, Calles A, Wu F, Lopes G, Sriuranpong V, Tanizaki J, Horinouchi H, Garassino MC, Popat S, Besse B, Rosell R, Soo RA
Lung Cancer: Targets and Therapy 2024, 15:87-114
Published Date: 22 June 2024
ATTLAS, IMpower151 and ORIENT-31: Dusting off IMpower150 for Post-Osimertinib in EGFR-Mutated NSCLC?
Lee JB, Ou SI
Lung Cancer: Targets and Therapy 2024, 15:81-85
Published Date: 25 May 2024
LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC
Lee ATM, Ou SI
Lung Cancer: Targets and Therapy 2024, 15:75-80
Published Date: 23 May 2024
“ACHILLES” Heel No More? Afatinib at 40 Mg Once Daily is Superior to Platinum-Based Chemotherapy in EGFR Uncommon (G719X, S768I, and L861Q) Mutations (ACHILLES/TORG1834)
Luo FX, Ou SI
Lung Cancer: Targets and Therapy 2024, 15:69-73
Published Date: 18 May 2024
Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver
Lee ATM, Ou SI
Lung Cancer: Targets and Therapy 2024, 15:19-27
Published Date: 27 February 2024
Stage as the Sole “Biomarker” for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091?
Nagasaka M, Ou SI
Lung Cancer: Targets and Therapy 2023, 14:101-109
Published Date: 12 December 2023
ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia
Lee AT, Ou SI
Lung Cancer: Targets and Therapy 2023, 14:71-78
Published Date: 7 July 2023
The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?
Brazel D, Ou SI
Lung Cancer: Targets and Therapy 2023, 14:63-69
Published Date: 23 June 2023
From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting
Lee AT, Ou SI
Lung Cancer: Targets and Therapy 2023, 14:57-62
Published Date: 22 June 2023
CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
Brazel D, Kim J, Ou SI
Lung Cancer: Targets and Therapy 2023, 14:31-39
Published Date: 20 April 2023
Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno
Brazel D, Ou SI, Nagasaka M
Lung Cancer: Targets and Therapy 2023, 14:1-9
Published Date: 5 January 2023
Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, “uncommon-G719X, S768I, L861Q”) Among the Third-Generation EGFR TKIs?
Zhang SS, Ou SI
Lung Cancer: Targets and Therapy 2022, 13:67-73
Published Date: 25 October 2022
Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
Zhang SS, Ou SI
Lung Cancer: Targets and Therapy 2022, 13:23-31
Published Date: 26 April 2022
ORIENT-31 as the Sakigake “Charging Samurai” Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the “Meiji Modernization” of Post-3G EGFR TKI Progression?
Nagasaka M, Ou SI
Lung Cancer: Targets and Therapy 2022, 13:13-21
Published Date: 29 March 2022